Transgenomic, Inc. Announces Strategic Relationship with ARUP Laboratories
Source: Transgenomic, Inc.
OMAHA, Neb., Jan. 30 -- Transgenomic, Inc.
Nasdaq: TBIO) today announced that the company has entered into a
strategic relationship with ARUP Laboratories of Salt Lake City, Utah.
Transgenomic will provide reference laboratory services to ARUP for the
analysis of patient samples for mitochondrial DNA mutations, and mutations
for other disorders. Transgenomic has developed expertise in analyzing the
whole mitochondrial genome, and proprietary tools have allowed the company
to detect mutations in samples with less than 5% of mutated DNA.
In making the announcement, Transgenomic's President and Chief
Executive Officer, Craig Tuttle, stated, "We are very excited to enter into
a relationship with ARUP Laboratories. ARUP is one of America's leading
clinical diagnostic laboratories serving over 3,000 hospitals today. This
relationship will enable Transgenomic to provide a critical diagnostic
service to hundreds of patients with mitochondrial disorders."
Noriko Kusukawa, PhD, Vice President and Director of New Technology
and Licensing at ARUP Laboratories, stated, "Mitochondrial diseases are a
clinically heterogeneous group of disorders and are often difficult to
diagnose. The incidence of this disease is much higher than previously
thought and impacts about 1 in 8,500 individuals in the U.S. Transgenomic
has expertise in mitochondrial genome analysis, and our relationship with
Transgenomic will enable ARUP to provide a much needed diagnostic service
to physicians for the management of these serious diseases."
About Transgenomic: A decade of discovery 1997—2007
Transgenomic is a global biotechnology company that provides unique
systems, products, discovery and laboratory testing services to the
academic and medical research, clinical and pharmaceutical markets for
automated high sensitivity genetic variation and mutation analysis in the
fields of pharmacogenomics and personalized medicine. This is accomplished
through their offerings of WAVE(R) DHPLC Systems, reagents, consumables and
assay kits, automated cytogenetics systems and Transgenomic Discovery and
CLIA Lab Services. To date there have been over 1,200 WAVE systems
installed in over 600 customer sites in over 35 countries and approximately
1,500 publications utilizing Transgenomic products or services.
Transgenomic Discovery and Lab Services utilize their technology and
expertise to provide a menu of mutation scanning tests for over 700
cancer-associated genes and more than 60 validated diagnostic tests to meet
the needs of pharmaceutical and biotech companies, research and clinical
laboratories, physicians and patients. For more information about the
innovative systems, products and services offered by Transgenomic, please
Transgenomic Cautionary Statements
Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Forward-looking statements
include, but are not limited to, those with respect to management's current
views and estimates of future economic circumstances, industry conditions,
company performance and financial results, including the ability of the
Company to grow its involvement in the diagnostic products and services
markets. The known risks, uncertainties and other factors affecting these
forward-looking statements are described from time to time in
Transgenomic's reports to the Securities and Exchange Commission. Any
change in such factors, risks and uncertainties may cause the actual
results, events and performance to differ materially from those referred to
in such statements. Accordingly, the company claims the protection of the
safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 with respect to all statements
contained in this press release. All information in this press release is
as of the date of the release and Transgenomic does not undertake any duty
to update this information, including any forward-looking statements,
unless required by law.
About ARUP Laboratories
ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and an enterprise of the University of Utah and its Department of Pathology. With more than 2,000 employees, ARUP offers in excess of 2,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays, for patients throughout the country. Rather than competing with its clients for physician office business, ARUP chooses instead to support clients' existing test menus by offering highly complex and unique tests, with accompanying consultative support, to enhance their abilities to provide local and regional laboratory services. ARUP's clients include more than half of the nation's university teaching hospitals and children's hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®.
ARUP Contact Information:
Ronald L. Weiss, MD, MBA
President and Chief Operating Officer